DARE Projected Dividend Yield
Dare Bioscience Inc ( NASDAQ : DARE )Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Co.'s U.S. Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. 21 YEAR PERFORMANCE RESULTS |
DARE Dividend History Detail DARE Dividend News DARE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |